Objective To compare the clinical efficacy and safety of warm versus room-temperature saturated saline soaking for the treatment of multiple plantar warts. Methods Sixty patients with multiple plantar warts were randomly assigned to a room-temperature group and a warmsaline group(n=30 each). Both groups underwent foot soaking in saturated saline prepared with food-grade refined salt conforming to GB 2721-2015 for 30 minutes once daily for 8 consecutive weeks. The soaking temperature was maintained at 26-35 ℃ in the room-temperature group and at 41 ℃ in the warm-saline group. Clinical efficacy was evaluated at weeks 2,4,6, and 8; the time to complete wart clearance was recorded among patients who achieved complete clearance; local adverse reactions were observed; and all cured patients were followed up for 6 months to assess recurrence. Results At weeks 2,4, and 6, there were no significant between-group differences in the complete clearance rate or overall response rate(all P＞0.05). At week 8, the complete clearance rate was significantly higher in the warm-saline group than in the room-temperature group(86.67% vs. 60.00%, P＜0.05); the overall response rates at all time points showed no statistically significant difference between groups(all P＞0.05). The time to complete wart clearance was 4(4-6)weeks in both groups, with no significant between-group difference(P＞0.05). No local adverse reactions were observed in either group throughout treatment. At 6-month followup, no new warts developed at the original lesion sites or within 3 cm of the surrounding skin among patients who had achieved complete clearance, and no recurrences were recorded. Conclusions Warm saturated saline soaking resulted in a higher complete clearance rate in the long-term period for multiple plantar warts compared with room-temperature saturated saline. Short-term lesion improvement, wart regression speed, safety profile, and long-term recurrence risk were comparable between the two groups. This therapy is non-invasive, cost-effective, and easy to administer, making it a viable option for home-based management of multiple plantar warts.
We report three cases of acneiform eruption induced by EGFR-TKIs. Three middleaged or elderly patients with lung cancer presented with acneiform eruptions of varying severity involving the face, neck, back and buttocks after treatment with icotinib or gefitinib. Dermatological examination revealed erythema and papules on the face in patient 1; erythema, pustules, desquamation on the face in patient 2; papules, erythema and pustules on the neck, back and buttocks in patient 3. Histopathological examination of skin lesions from patients 2 and 3 revealed neutrophilic infiltration in the dermis. Histopathological data were unavailable for patient 1. A diagnosis of acneiform eruption was made in all three patients. After treatment with oral doxycycline and other supportive therapies, the eruptions improved. EGFR-TKI was continued throughout dermatologic treatment in all three patients. The skin eruption continued to improve during 2~3 week's follow-up.
As an effective therapeutic strategy for malignant neoplasms, boron neutron capture therapy(BNCT)has demonstrated promising clinical outcomes across various cutaneous malignancies. Multicenter studies in melanoma have reported complete response rates of 73% -78%, an overall disease control rate of 88%, and a 5-year disease-specific survival of 58%, with manageable toxicities including cutaneous radiation injury. For genital melanoma and extramammary Paget disease, BNCT has shown promising efficacy. In the first-in-human phase Ⅰ trial for cutaneous angiosarcoma, BNCT achieved a best overall response rate of 70% and a 2-year overall survival rate of 90.0%. Additionally, BNCT has exhibited therapeutic potential in cutaneous metastases and soft tissue sarcomas with cutaneous or subcutaneous involvement. This review systematically summarizes clinical advances in BNCT for cutaneous malignancies and discusses its clinical feasibility, current limitations, and future prospects.
Acquired reactive perforating collagenosis(ARPC)is a refractory pruritic dermatosis closely associated with systemic diseases, and conventional treatments often have limited efficacy. Recent studies have suggested that type 2 inflammation and the key cytokines IL-4/IL-13 may be involved in its pathogenesis. As a monoclonal antibody targeting IL-4Rα, dupilumab can simultaneously block the IL-4/IL-13 signaling pathway, providing a potential therapeutic option for ARPC. This review summarizes the pathogenesis of ARPC, the mechanism of action, clinical efficacy and safety of dupilumab, analyzes the limitations of current evidence, and outlines future research directions, with the aim of informing the diagnosis and management of ARPC.
Vitiligo is a chronic inflammatory skin disorder characterized by acquired depigmentation and involves complex interactions among oxidative stress, genetic susceptibility, immune dysregulation, and microenvironmental abnormalities. Emerging evidence indicates that innate immune activation plays a pivotal role in both the initiation and maintenance of disease activity in vitiligo. Oxidative stress-induced melanocyte promotes the release of damage-associated molecular patterns, which activate pattern recognition receptors, including Toll-like receptors, NOD-like receptors, and the receptor for advanced glycation end products. This process subsequently activates dendritic cells, natural killer cells, and innate lymphoid cells, thereby amplifying inflammatory cascades and promoting adaptive immune activation through the IFN-γ/CXCL9/CXCL10 axis. In addition, emerging mechanisms such as ferroptosis, cuproptosis, and exosome-mediated immune regulation have been implicated in melanocyte injury and amplification of inflammation. With advances in reflectance confocal microscopy, optical coherence tomography, multiphoton microscopy, and serum biomarker assays, evaluation of vitiligo activity has gradually shifted from conventional morphological assessment toward dynamic, and precision-oriented monitoring based on disease-mechanisms. This review summarizes the core mechanisms of innate immune activation in vitiligo and their interactions with adaptive immunity, with particular emphasis on recent advances in noninvasive imaging, molecular biomarkers, multi-omics approaches, and artificial intelligenceassisted monitoring strategies. Current limitations and future perspectives for clinical translation are also discussed to inform precision diagnosis and individualized management of vitiligo.
Objective To analyze the results and distribution characteristics of four preoperative bloodborne infection markers among dermatology patients. Methods A retrospective analysis was conducted on the results of the four preoperative infectious disease markers(HBsAg, antiHCV, anti-TP, and HIV Ag/Ab)from 21 406 dermatology patients treated at the Dermatology Hospital, Southern Medical University between 2022 and 2023. Systematic screening and statistical analysis were performed to compare differences in positive rates between outpatients and inpatients, and across sex and age groups, and to analyze pattern of multiple-marker positivity. Results The overall positivity rate for the four preoperative markers among the 21 406 patients was 10.57%(2 263/21 406). The positive rates for each individual marker were as follows: HBsAg 6.46%(1 382/21 406, highest in the 31-40-year age group), anti-TP 3.06%(655/21 406, highest in the 21-30-year age group), anti-HCV 0.80%(172/21 406; highest in the 41-50-year age group), and HIV-Ag/Ab screening reactivity 0.25%(54/21 406; highest in the 31-40-year age group), pending confirmatory testing. The differences in the positivity rates of these four markers between outpatients and inpatients were all statistically significant(all P＜0.05). Except for anti-HCV, positivity rates for the other three markers differed significantly by sex(P＜0.05). The age distribution of patients testing positive for each marker showed statistically significant differences. A total of 114 cases of co-infection were identified, with HBsAg combined with antiTP being the most common(56 cases,49.12%). Conclusions The positivity rate of preoperative bloodborne infection markers was relatively high among dermatology patients and exhibits specific demographic characteristics. The positivity rate was higher among inpatients than among outpatients. Routine preoperative infection screening is crucial for identifying high-risk populations, implementing targeted occupational safety measures, and reducing the risk of healthcare-associated transmission and medicolegal disputes.
Psoriasis is a chronic inflammatory disease involving immune dysregulation, abnormal proliferation of keratinocytes(KCs), and neurogenic inflammation, with its molecular mechanisms not yet fully elucidated. Ion channels, as core components of cellular signal transduction, play a pivotal regulatory role in these pathological processes. This article systematically summarizes recent advances in the roles of transient receptor potential(TRP)channels, potassium channels, calcium channels, purinergic P2X receptors(P2XR), and mechanosensitive Piezo channels in the dysfunction of KCs, immune-mediated inflammation, and neuro-immune-skin interactions in psoriasis. For the first time, it proposes a“Ca2+ signaling pathway network-chronic inflammation loop-neural sensitization”cascade amplification integration model, illustrating how different types of ion channels synergistically drive disease progression within the psoriatic microenvironment. Additionally, this review summarizes advances in the clinical translation of ion channel-targeted therapies, with a focus on the development status and challenges of candidate agents such as Kv1.3 inhibitors, calcium release-activated calcium(CRAC)channel antagonists, and TRPV channel modulators, aiming to provide new insights for precision-targeted treatment of psoriasis.
Objective To evaluate the short-term efficacy and safety of xeligekimab in patients with severe plaque psoriasis based on real-world data, and to perform an exploratory comparison with patients treated with secukinumab during the same period. Methods The clinical data of eligible patients with severe plaque psoriasis treated at the Department of Dermatology, Kaifeng People's Hospital, between September 2024 and December 2025 were retrospectively analyzed. The xeligekimab group included 23 patients, while the control group comprised 23 patients selected from 52 patients who received secukinumab during the same period using propensity score matching with a caliper value of 0.02. A total of 46 patients were included in the final analysis. The psoriasis area and severity index(PASI)scores and PASI 75/90/100 response rates were com pared between the groups at baseline and at weeks 4 and 12. Investigator global assessment (IGA)scores and adverse reactions were also recorded. Results After matching, baseline characteristics showed no statistically significant differences between the two groups(all P values ＞0.05). At weeks 4 and 12, PASI scores decreased significantly compared with baseline in both groups(xeligekimab group: t=20.75 and 24.23, respectively; secukinumab: t=20.85 and 23.01, respectively; all P＜0.001). IGA scores also decreased significantly at week 12 in both groups(xeligekimab: Z=-4.28; secukinumab: Z=-4.26; both P＜0.001). No significant between-group differences were observed in PASI 75/90/100 response rates at weeks 4 and 12(all P values ＞0.05). The overall incidence of adverse events was 8.70%(2/23)in the xeligekimab group and 13.04%(3/23)in the secukinumab group, with no statistically significant difference(P=1.000). Conclusions Xeligekimab showed favorable short-term efficacy and acceptable safety in the treatment of severe plaque psoriasis. The secukinumab reference group showed a similar pattern of clinical improvement. However, given the non-randomized, exploratory nature of this study, these findings warrant further validation in prospective studies.
We report a case of inverted follicular keratosis(IFK)with seborrheic keratosis (SK). A 69-year-old man presented with a black-brown nodular with ulceration and recurrent bleeding on the left cheek for more than six months. Dermatological examination revealed a blackbrown nodule measuring approximately 1.5 cm × 0.6 cm on the left cheek. The lesion was elevated, with a rough surfaced and focal verrucous changes. It was firm, non-tender, and without induration at the base. Histopathological examination of the excised specimen showed hyperkeratosis, acanthosis, and papillomatosis. The proliferating cells consisted of basaloid cells and squamous cells, with pseudohorn cysts and squamous eddies. Increased numbers of neutrophils and lymphocytes were observed around the hair follicles and blood vessels, along with neutrophilic infiltration in the interlobular septa of the subcutaneous fat. The final diagnosis was IFK coexisting with SK. The lesion was completely excised, with no recurrence during 1-year of follow-up.
Objective To investigate whether macrophage ferroptosis occurs in atopic dermatitis(AD)lesions and its role in AD, and to elucidate the mechanism by which 4-octyl itaconate(4-OI)alleviates AD inflammatory skin damage by inhibiting oxidative stress and macrophage ferroptosis. Methods A total of 40 male C57BL/6 mice were used. Fifteen mice were randomly assigned to 3 groups(n=5 each): the blank control group received no treatment, and the other two groups were treated with calcipotriol(MC903)to establish the AD model. Skin lesions were collected on days 0,7, and 14 post-modeling to observe histopathological changes, mRNA expression of IL-4, IL-5, and IL-13, and macrophage infiltration. Another 10 mice were randomly divided into sham and MC903-model groups(n=5 each). The sham group received topical ethanol, while the MC903-model group received topical MC903 for 14 consecutive days. The levels of oxidative stress, macrophage ferroptosis, and markers of the endogenous itaconate/Nrf2 pathway (Acod1, GPX4, PTGS2, Nrf2, and HO-1)in skin lesions were compared between the two groups. A further 15 mice were randomly divided into sham, MC903-model, and MC903 +4-OI treatment groups(n=5 each). Mice in the MC903+4-OI group received intraperitoneal injection of 4-OI(50 mg/kg)concurrently with MC903 application for 14 consecutive days to evaluate the therapeutic effect of 4-OI on AD skin lesions. Histopathological changes were assessed by H&E staining. The expression levels of type 2 inflammatory cytokines(IL-4, IL-5, IL-13), ferroptosisrelated markers, and GPX4, PTGS2, Nrf2, and HO-1 were detected by real-time quantitative PCR and Western blotting. Macrophage infiltration was examined by immunofluorescence. Oxidative stress was evaluated by ELISA for malondialdehyde(MDA)levels and by flow cytometry for DCFDA+ macrophages in lesional skin. Results Over time following MC903 induction, the epidermis of lesional skin in the model group showed progressive thickening(P＜0.05), along with elevated levels of type 2 inflammatory cytokines IL-4, IL-5, and IL-13(P＜0.01)and increased macrophage infiltration. Compared with the sham group, the ferroptosis marker GPX4 was downregulated and PTGS2 was abnormally upregulated(P＜0.01), while Acod1, Nrf2, and HO-1 were upregulated(P＜0.01). Concurrently, increased malondialdehyde(MDA)content and an elevated proportion of DCFDA+ macrophages in lesional skin were observed(P＜0.01). In contrast, treatment with 4-OI significantly ameliorated skin lesions(P＜0.01), reduced the levels of IL-4, IL-5, and IL-13(P＜0.01), suppressed macrophage ROS and MDA production, and reversed the abnormal expression of GPX4 and PTGS2(P＜0.05)compared with the MC903 model group. Conclusions Macrophage ferroptosis is present in AD skin lesions, and 4-OI attenuates skin inflammatory damage by suppressing oxidative stress and macrophage ferroptosis.
Objective To summarize the cutaneous histopathological features of patients with dermatomyositis(DM), identify histopathological clues in patients with concomitant malignancies, and investigate histopathological differences among subtypes of myositis antibodies. Methods A total of 38 patients diagnosed with DM who underwent skin biopsy from January 2017 to October 2025 were retrospectively enrolled. The results of hematoxylin-eosin(HE)staining and direct immunofluorescence(DIF)were collected. A histopathological evaluation system consisting of 13 binary variables and 5 ordinal variables was established. According to the presence of concomitant malignancy, patients were divided into the cancer-associated myositis(CAM)group(n=6)and the non-cancer-associated myositis(Non-CAM)group(n=32). Based on the myositis antibody profile, patients were further subclassified into transcription intermediary factor 1-γ(TIF1-γ), Mi-2, melanoma differentiation-associated protein 5(MDA5), nuclear matrix protein 2(NXP2), small ubiquitin-like modifier activating enzyme 1(SAE1), myositis-associated antibody(MAA), and seronegative subgroups. The cutaneous histopathological features of each group were summarized, and intergroup differences were analyzed. Results HE staining revealed lymphocytic infiltration at the dermoepidermal junction in all patients(100%). Common histopathologic features included basal cell liquefactive degeneration(86.84%), spongiosis(81.58%), edema of superficial dermal collagen fibers(81.58%), and pigment incontinence(78.95%). Among the 32 patients who underwent DIF,12(37.50%)were negative for all tested markers, whereas 12 (37.50%)had at least two positive DIF findings. Immunoglobulin M(IgM)deposition along the basement membrane zone(BMZ)was the most frequent finding(50.00%), whereas immunoglobulin A(IgA)deposition was the least frequent(3.13%). Compared with the Non-CAM group, the CAM group had a higher frequency of intracellular edema within the spinous layer (66.67% vs. 12.50%, P=0.012), as well as higher dyskeratosis scores(1.5 vs. 0.0; P=0.048)and basal cell liquefactive degeneration scores(2.0 vs. 1.0; P=0.032). The cutaneous histopathology of all antibody subtypes was dominated by the interface injury shared by DM. Conclusions The core histopathologic features of DM skin lesions are lymphocytic infiltration at the dermoepidermal junction and basal cell liquefactive degeneration. IgM deposition along the BMZ is the most common DIF finding and may aid in diagnosis. Compared with the Non-CAM group, the CAM group more frequently exhibited intracellular edema and showed more severe dyskeratosis and basal cell liquefactive degeneration, suggesting that these histopathologic changes may be associated with an increased risk of malignancy.
A case of Marshall-White syndrome is reported.A 27-year-old male presented with leukoplakia on the upper limbs that had increased progressively for over four years.Multiple scat-tered round or quasi-round white spots with a diameter of about 0.2-1.0 cm could be seen on the upper limbs.The lesion boundary was clear, and the surface was smooth and free of scales.The white spots could be seen to fade or even disappear after rubbing or raising the arms.The dermo-scopic examination showed a white unstructured area with a light red background and multiple scattered punctate globular telangiectasia around the upper limbs.After the upper limbs were lifted or rubbed, the background skin color could be seen, the white unstructured area was obviously lighter than before, and the original dot globular telangiectasia around it was significantly reduced. The diagnosis was Marshall-White syndrome.No treatment was given.
Objective This study aimed to evaluate the synergistic effect of berberine hydro-chloride on the antibacterial activity of penicillin against Penicillinase-Producing Neisseria gonor-rhoeae（PPNG）, offering new insights for the prevention and treatment of highly drug-resistant PPNG.Methods The minimum inhibitory concentration（MIC）of berberine hydrochloride com-bined with penicillin against PPNG strains were determined using microbroth dilution and checker-board assays, with fractional inhibitory concentration（FIC）indices calculated to assess antibacte-rial efficacy.TEM DNA mutations were detected via gene sequencing.TEM mRNA expression levels were measured by RT-qPCR.Penicillinase was extracted by ultrasonic disruption, and its activity was assessed using the dual-wavelength colorimetric Amplite assay kit.Results The MIC range of the berberine hydrochloride-only treatment against PPNG was 0.03～128 μg/mL. The MIC of penicillin decreased by ≥4-fold and the FIC index was ≤0.5 when berberine hydrochlo-ride was combined with penicillin against PPNG, demonstrating the synergistic antibacterial effects of these two compounds.The combined antibacterial strategy did not induce mutations in TEM genes, but it decreased penicillinase activity（P＜0.05）through downregulating the mRNA ex-pression of TEM（2-ΔΔCt＜1）.Conclusions Berberine hydrochloride not only directly inhibits PPNG growth but also restores penicillin sensitivity by down-regulating TEM gene expression and inhibiting penicillinase activity.These findings showed that berberine hydrochloride is an antibiotic adjuvant against PPNG.
Keloids have a high recurrence after surgical excision and are hard to completely cure.Postoperative radiotherapy has become a comprehensive treatment for keloid after surgical excision and is widely used in clinical practice.Postoperative radiotherapy significantly reduces re-currence rates and improves treatment efficacy by inhibiting abnormal fibroblast proliferation and excessive collagen deposition, while maintaining an overall acceptable safety profile with mild, preventable adverse reactions.The intervention timepoint and radiotherapy dose are key parame-ters influencing clinical outcomes.Early intervention within 2 hours post-surgery yields optimal ef-ficacy, with single-dose 1 0 Gy electron-beam radiotherapy or 20 Gy fractionated into 5 low-dose sessions as preferred clinical regimens.A safe and effective treatment window is within 24 hours. Compared with radiotherapy alone, combined regimens such as postoperative radiotherapy com-bined with botulinum toxin type A injections or refined suturing techniques can further optimize scar repair and reduce the risk of recurrence.In addition, the efficacy of radiotherapy varies across populations and body sites.Specifically, the high-tension skin areas and younger patients are at a higher risk of recurrence, making them candidates for postoperative radiotherapy.In sum-mary, postoperative radiotherapy is an efficient and safe adjuvant after surgical excision.Personal-ized radiotherapy dose, treatment timepoint, and combined regimens, patient education, and im-proved multidisciplinary collaboration enhance the efficacy and mitigate risks.In the future, we should extend to large-sample, high-quality studies to promote personalized medicine.
Scars represent a common outcome of aberrant tissue remodeling following wound healing.The hypertrophic scars and keloids cause pain, pruritus, cosmetic disfigurement, and functional impairment, which carry significant psychological and social consequences for patients. Scar management has shifted from single-modality treatment to a multidisciplinary strategy incorpo-rating risk stratification, early intervention, and multimodal therapy.We reviewed the recent pro-gresses in scar management including clinical guidelines, randomized controlled trials, silicone-based prevention, pressure therapy, tension-reduction techniques, intralesional corticosteroids,5-fluorouracil（5-FU）, bleomycin, and botulinum toxin type A（BoNT-A）, vascular and ablative laser therapy, laser-assisted drug delivery, surgery combined with adjuvant radiotherapy, and e-merging approaches such as regenerative medicine, exosomes, tissue engineering, and nano-ena-bled delivery et al.Current studies have shown that silicone, tension reduction, and pressure ther-apy are suitable for early prevention; the intralesional and energy-based therapies are suitable for active lesions; and the excision is not the only strategy because of the high recurrence risk.Future investigations are required for precision treatment guided by the standardized outcomes, patient-re-ported measures, long-term follow-up and molecular profiling.
Facial aging is a degenerative process involving the skin, subcutaneous fat, and skeletal structures, which is characterized by skin laxity, volume loss, blurred contours, and the coexistence of dynamic and static wrinkles.Currently, single-modality treatments are insufficient to address increasingly complex aging concerns, whereas comprehensive anti-aging strategies have emerged as the primary clinical management approach for facial aging due to their synergistic effects, prolonged efficacy, and reduced side effects.This review summarized the multilayered physiological mechanisms underlying facial aging, including epidermal atrophy, dermal degrada-tion of collagen and elastin, subcutaneous fat atrophy, ligamentous laxity, and muscular tension imbalance.We also reviewed the assessment methods of facial aging, including Glogau grading, Fitzpatrick skin typing, VISIA imaging, and 3D modeling.Furthermore, we proposed a personal-ized combination therapy principle based on aging stages, skin types, and individual needs, and detailed the synergistic mechanisms and representative protocols integrating injectables, energy-based devices, and regenerative therapies.Finally, this review emphasizes the treatment se-quence, complication prevention, and long-term maintenance, aiming to provide a scientific and systematic framework for facial rejuvenation in the clinic.
Melanoma is a malignant skin tumor characterized by high invasiveness and metasta-sis.Genomic mutations drive dysregulation of the immune microenvironment and the intracellular signaling network in melanoma.These pathways can be functionally classified into three catego-ries:key pathways governing tumor initiation and progression, such as MAPK and PI3K/AKT, which drive cell proliferation and metabolic reprogramming via BRAF; phenotypic and invasive pathways, including TGF-β/Smad, Wnt/β-catenin and Notch, which multidimensionally regulate epithelial-mesenchymal transition and malignant progression; microenvironmental and immune es-cape pathways, such as NF-κB, Hedgehog, PD-1 /PD-L1 and cuproptosis, which reshape tumor phenotypes by coupling redox homeostasis with immune suppression.Here, we reviewed the signa-ling pathways associated with melanoma and summarized novel biotherapeutic strategies across four aspects:gene editing and transcriptional regulation, nucleic acid-targeted therapy, novel delivery carriers and biological agents, and natural active molecules and small-molecule targeted therapy, aiming to provide new insights for the precise intervention in melanoma.
We report a case of primary cutaneous mucinous carcinoma.A 74-year-old male was diagnosed with a small lesion located on the lower eyelid of his right eye three years ago.The lesion had progressively enlarged over the past six months.Dermatological examination showed a purple lesion on the lower eyelid of the right eye, approximately 4 cm ×3 cm, characterized by a clear boundary, a soft texture and dilated capillaries.Further ultrasonography suggested a potential malignant transformation with a cystic-solid lesion.Immunohistochemistry（IHC）confirmed the primary skin mucinous carcinoma with CK7（+）, CK20（-）, CDX2（-）, TTF -1（-）, MSH2 （+）, MSH6（+）, MLH1（+）, PMS2（+）, HER2（0）, GATA-3（+）.Subsequently, the sur-gical intervention involved local enlarged excision of the lesion in the lower right eyelid with pedi-cle muscle flap transfer, as well as peripheral nerve entrapment release and repair of the facial de-fect under general anesthesia.IHC examinations confirmed that the primary skin mucinous carci-noma showed no capsule invasion, vascular, or neural infiltration.Immunohistochemistry demon-strated CK7（+）, ER（+, strong, positive rate 90%）, PR（+, strong, positive rate 80%）, AR（+, strong, positive rate 90%）, Ki-67（+, approximately 1 5%）, P53（weak+, approxi-mately 40%）, GCDFP1 5（partially+）, GATA-3（+）, Villin（-）, CK20（-）.The patient is still under follow-up.
Objective To investigate the effects of intense pulsed light（IPL）combined with chemical peeling on skin surface physiological parameters in patients with mild to moderate acne. Methods One hundred and twenty patients with mild to moderate acne who visited the Depart-ment of Dermatology at Emergency General Hospital from January 2024 to June 2025 were enrolled in this study.The cohort was randomly divided into three groups（40 patients per group）:Group A received IPL only; Group B received chemical peeling only; and Group C received both IPL and chemical peeling.The treatment course lasted three months, with monthly intervals.The clinical efficacy, incidence of adverse reactions, and skin surface physiological parameters were compared among three groups.Results Group C achieved 1 00% effectiveness, while Group A and Group B were both 97.50%.However, there were no statistically significant differences in treatment effec-tiveness among the three groups（P=0.600）.Before treatment, there were no significant differ-ences in surface pigment area, pore count, porphyrin count, or skin smoothness among the three groups of patients（F=0.22,0.05,0.1 6,0.1 7; P=0.804,0.952,0.856,0.847, respective-ly）.After treatment, there were significant differences in surface pigment area, pore count, por-phyrin count, and skin smoothness among the three groups（F=8.92,3.48,25.44,28.38, re-spectively; P＜0.001, P=0.034, P＜0.001, P＜0.001, respectively）.Further pairwise com-parisons showed that the surface pigment area in Group C was lower than that in Group A and Group B（t=3.69,3.62, respectively, both P＜0.001）, the pore count in Group C was lower than that in Group A and Group B（t=2.28,2.29, respectively; P=0.025 and 0.024）, the porphyrin count in Group C was lower than that in Group A and Group B（t=6.52 and 5.76, both P＜0.001）, and the skin smoothness in Group C was higher than that in Group A and Group B（t=-6.09, -6.89, respectively, both P＜0.001）.There was no significant difference in the incidence of adverse reactions among the three groups（P=0.857）.Conclusions Intense pulsed light combined with chemical peeling can effectively improve the skin color of patients with mild to moderate acne, reduce the number of pores and porphyrin fluorescence intensity, and the effect is significant.
Objective To investigate the clinical features, diagnostic clues, and management of mycosis fungoides（MF）presenting with palmoplantar eczema-like lesions.Methods A retro-spective analysis of the clinical data of a patient with MF initially misdiagnosed as palmoplantar ec-zema was conducted.Diagnosis was confirmed by histopathology from multiple sites, immunohisto-chemistry, and T-cell receptor（TCR）gene rearrangement analysis.Results The patient had a 4-year history of refractory palmoplantar lesions and had failed multiple systemic therapies.Re-peated biopsies confirmed MF.Treatment with methotrexate, combined with local radiotherapy and phototherapy, resulted in marked improvement in erythema, infiltration, and scaling.Conclusions MF should be considered if a patient has chronic palmoplantar eczema-like lesions that are per-sistent or treatment-resistant.Immunophenotyping and TCR clonality analysis of the repeated biop-sies are necessary for accurate diagnosis and timely treatment.
